Dr. Victor L. Carlo Chévere

Assistant Professor

Contact Info

  • University of Puerto Rico
    Medical Sciences Campus
    School of Medicine
    Gastroenterology Section
  • 787-754-0101, Ext. 2418, 5445

Education

  • Degree: M.D. Ponce School of Medicine, M.D., 1997                
  • Degree: B.S. University of Puerto Rico, Mayaguez Campus, 1993

ACADEMIC POSITIONS

Instructor of Medicine – UPR School of Medicine, 2000 to 2003

Chief Fellow, Gastroenterology fellowship, UPR School of Medicine, 2002-2003

Assistant Professor of Medicine-UPR School of Medicine, 2003 to present

Assistant Director, Gastroenterology Research Unit, 2005 to present

Assistant Director, UPR Gastroenterology Training Program, 2005-2010

Program Director, UPR Gastroenterology Training Program, 2009 – present

Chief, UPR School of Medicine – Division of Gastroenterology, 2015 – present

RESEARCH INTEREST

Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV)

Infection. Original Approval Start: 03/07/2017 – Current Approval Period: 02/15/2018 – 02/15/2019

Familial Colorectal Cancer in Puerto Rico: A Feasibility Study. Original Approval Start: 06/07/2007. Current Approval Period: 01/18/2018 – 01/18/2019.

Targeted chemoprevention of gastric carcinogenesis in high-risk populations. Original Approval Start: 05/18/2017. Current Approval Period: 05/18/2018 – 05/18/2019

Randomized, double-blind, placebo-controlled trial of Meriva® (curcumin) as a candidate chemoprevention agent for gastric carcinogenesis. Original Approval Start: 03/29/2017. Current Approval Period: 04/2/2018 – 03/21/2019

Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis. Original Approval Start: 01/31/2018. Current Approval Period: 05/25/2018 – 05/23/2019

A double Blind, Randomized, 6-week, Parallel group design clinical Trial to Assess Safety and Efficacy of Asacol 4.8g/day (800mg Tablet) versus Asacol 2.4g/day (400mg Tablet) for the treatment of mildly to moderately active ulcerative colitis.

Histologic changes in the liver after treatment with Interferon and RIBAVIRIN for chronic Hepatitis C.

Screening of TNF microsatellite polymorphisms as potential markers for genetic risk of chronic inflammatory disease in Puerto Ricans.

Surveillance for Dyplasia from pouches in patients with Ulcerative Colitis with Ileal Pouch-Anal anastomosis.

Inflammatory Bowel Disease Patient Serum Bank.

A Phase III, Double Blind, Multicenter, Randomized, Placebo-Controlled Study of the

Effects of a Somastostatin Analogue-Lanreotide as an Adjuvant to Endoscopic Band Ligation of Patients with Acute Bleeding from Esophageal Varices Secondary to Cirrhosis and Portal Hypertension.

Health Related Quality of Life in Inflammatory Bowel Diseases Patients in Puerto Rico.

Inflammatory Bowel Disease Registry in Puerto Rico.

PUBLICATIONS

Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry. Torres EA1, Cruz A, Monagas M, Bernal M, Correa Y, Cordero R, Carlo VL. Int J Inflam. 2012; 2012:574079 Doi: 10.1155/2012/574079. Epub 2011 Dec 11, 2011.

Medication profiles of patients in the University of Puerto Rico inflammatory bowel disease registry. Meléndez JD1, Larregui Y, Vázquez JM, Carlo VL, Torres EA. P R Health Sci J. 2011 Mar;30(1):3-8 2011.

Hepatocellular carcinoma at the University of Puerto Rico Liver Transplant Clinic. Rivera Resto M1, De Varona Negrón M, Eguía V, Carlo VL, Torres EA. P R Health Sci J. 2007 Dec;26(4):337-42 2007.

Carlo, VL: Fulminant Hepatic Failure.  Fellow Reporter 7: 15-18, 2002.

Romero CT, Torres EA, Rodríguez-Medina JR, Magno P, Antúnez I, Carlo V, Yang H, taylo K.  TNF microsatellite haplotypes in Puerto Rican’s with IBD.  American Jour Gastro 2001; 96: S 306 (970).